MolDX: NRAS Genetic Testing

MolDX covers somatic NRAS mutation testing on tumor tissue only for patients with metastatic colorectal cancer per NCCN Guidelines (Version 2.2016) to inform use of anti-EGFR therapies. All other NRAS testing—including testing for melanoma, other tumor types, and germline testing for Noonan syndrome—is not covered due to insufficient evidence of clinical utility; documentation must demonstrate tumor tissue testing and metastatic colorectal cancer diagnosis per NCCN guidance.

"Somatic NRAS mutation testing on tumor tissue is covered for patients with metastatic colorectal cancer, consistent with NCCN Guidelines (Version 2."

Sign up to see full coverage criteria, indications, and limitations.